 Puma Biotechnology Inc NASDAQ: PBYI announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH R132H mutation-negative. In the intent-to-treat population, progression-free survival PFS was not significantly longer with neratinib median 6.0 months versus the control arm median 4.7 months. 